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ABSTRACT
We described two cases of treatment-experienced HIV-infected patients who 
presented with cytomegalovirus uveitis and Cryptococcus neoformans adenitis 
as a manifestation of immune reconstitution inflammatory syndrome (IRIS) during 
salvage treatment. Little is known about IRIS in highly experienced patients, and this 
report suggests that IRIS should be considered in this setting if there is a favorable 
response to salvage therapy.
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The immune reconstitution inflammatory syndrome (IRIS) is characterized 
by an otherwise unexplained paradoxical onset of clinical and laboratorial 
manifestations of an opportunistic infection or inflammatory condition after 
recovery of CD4 T cells levels and function and  virologic suppression 
of >1 log 10 copies/mL in HIV RNA viral load following highly active 
antiretroviral therapy (HAART) initiation1. Proposed definitions for IRIS are 
usually limited to patients who are initiating HAART1-3. However, little is known 
about IRIS in treatment-experienced patients. In this report, we aimed to 
describe two recent cases of heavily pretreated patients who develop IRIS 
following salvage therapy, emphasizing that this syndrome is not limited to 
treatment-naïve patients who start HAART. 
CASE 1
The first case was a 44-year-old male HIV patient who had started 
HAART in 1997. This scheme was changed twice by July 2004, when his 
CD4 count was 98 cells/mm3 and the HIV load was 341,269 (log 5.53). 
His highest CD4 count had been 174 cells/mL in 2000, and his viral load 
had never been undetectable. In March 2005, the therapeutic scheme was 
as follows: tenofovir 300 mg once a day, lamivudine 150 mg twice a day, 
saquinavir 1000 mg twice a day, and lopinavir/ritonavir 400/100 mg twice a 
day, according to a viral resistance genotyping test. Three months latter, he 
complained of floaters and decreased visual acuity in the right eye. Indirect 
ophthalmoscopy revealed a cystoid macular edema and severe vitritis in the 
right eye. Signs of inactive cytomegalovirus retinitis were also observed. The 
left eye examination was unremarkable. The CD4 count was 247 cells/mm3 
and the HIV load was 1,492 copies/mL (log 3.17). The patient was initially 
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treated with ganciclovir 5mg/kg twice a day 
(three weeks), despite the absence of active 
cytomegalovirus retinitis, and with prednisone 
60mg/a day for two weeks, followed by a gradual 
reduction to 10mg/a day for 8 weeks. At the end of 
the treatment, vitritis was mild to moderate, and the 
patient still complained of blurred vision. A three-
month follow-up examination did not reveal any 
sign of vitritis nor of macular edema, but the patient 
remained with minimal visual complaints (slight 
blurred vision). The CD4 count was 187 cells/mm3, 
and the HIV load was undetectable.
CASE 2
The second case was a 33-year-old female 
patient who had been diagnosed with AIDS in 
2000. The CD4 cell count was unknown. The 
patient started HAART at the moment of diagnosis, 
but due to therapeutic failure the scheme was 
modified three times by September 2005, when 
she was admitted to the hospital with a diagnosis 
of disseminated cryptococcosis (Cryptococcus 
neoformans was recovered from the cerebrospinal 
fluid, cervical lymph nodes, and blood). The patient 
was then started on zidovudine 300 mg twice a 
day + lamivudine 150 mg twice a day + lopinavir/
ritonavir 400/100 mg twice a day. She was 
successfully treated with 15 days of amphotericin B 
1mg/kg/a day, followed by 8 weeks of fluconazole 
400 mg/a day orally, and then kept on suppressive 
therapy with fluconazole 200 mg/a day. In February 
2006, she was once again admitted to the hospital 
with cryptococcal lymphadenitis. Compliance to 
both HAART and suppressive fluconazole therapy 
was ensured. Meningeal involvement was ruled out. 
The hallmark of this presentation was the exuberant 
granulomatous reaction and the few encapsulated 
fungi found at histopathological examination of the 
lymph node, which contrasted with her first biopsy in 
September 2005, in which abundant fungal structures 
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and minimal inflammatory reaction were observed. 
Her CD4 count and viral load were 91 cells/mL and 
582 copies/mL (log 2.76). The patient was treated 
with amphotericin B and prednisone 0.5 mg/kg a day 
for 16 days and recovered well.
DISCUSSION
It is estimated that IRD may occur in 10-
25% of patients who start HAART and reach 
immune restoration1-3. The current report presents 
distinct features that must be highlighted, since 
it supports that immune reconstitution, although 
less frequently and less potently4,5, occurs with 
advanced disease and in HAART-experienced 
patients, even in those who have experienced 
multiple failures, and this immune recovery can 
be strong enough to trigger IRIS. 
In a recent cohort, being drug-naïve was an 
independent risk factor for IRIS6. This association 
is probably related to a more robust virological 
and immunological response to therapy by this 
group of subjects, when compared with those 
who had been on prior therapy4-6. Only four of 57 
patients who had developed IRIS were HAART-
experienced, compared with 38 of 123 patients 
who had not developed this syndrome6. Previous 
HAART experiences were not described for these 
four patients, and it is not known whether they 
presented multiple failures.
In both cases, many features support the 
diagnosis of IRIS, particularly the exuberant 
inflammatory responses. In the second case, 
notably, the CD4 count, which may be low in IRIS3, 
was below 100 cells/ml, but an increase is likely to 
have occurred, although the CD4 count prior to the 
latter treatment was unknown and this hypothesis 
could not be confirmed. 
In summary, IRIS should be considered even 
in the setting of multiple previous failures if there 
is favorable response to salvage therapy.
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